Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Net Receivables · Q2 FY2026 · quarter ended Mar 2026

Net receivables rises 387.7% from a year ago

Net receivables stood at CA$1.14M at the end of Q2 FY2026, up 387.7% from a year earlier and up 126.6% from the prior quarter. Over 3 fiscal years it compounded at +38.4% a year.

Context

  • Net receivables amounted to 0.4% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +387.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$1.14M+126.6% QoQ
Last fiscal yearSep 2025
CA$413.07K+722.5% YoY
Year agoMar 2025
CA$233.57K+387.7% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+387.7%——
1 year+722.5%——
3-year CAGR+38.4%——
5-year CAGR——
10-year CAGR——

Net Receivables history

CAD · from the balance sheet

Latest · FY2025
413.07K CAD
Year-over-year change
+722.5%
4-year CAGR
+39.2%

Net Receivables vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Net Receivables figures are available to compare.

Balance Sheet

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents19.76M11.63M6.75M5.72M82.91M
Short-term Investments00000
Net Receivables110.15K155.78K36.98K50.22K413.07K
Inventory00000
Other Current Assets00000
Total Current Assets20.04M11.95M6.81M5.99M84.31M
Property, Plant & Equipment (Net)0138.86K66.41K117.66K111.97K
Goodwill2K0000
Intangible Assets20000
Long-term Investments33.68K0000
Tax Assets00000
Other Non-current Assets(33.68K)(0)000
Total Non-current Assets2K138.86K66.41K117.66K111.97K
Total Assets20.04M12.09M6.88M6.1M84.42M
Account Payables596.57K1.25M182.31K407.55K1.71M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities638.57K1.47M280.86K528.68K2.34M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities071.98K039.58K41.25K
Total Liabilities638.57K1.54M280.86K568.26K2.38M
Common Stock27.08M32.24M33.91M35.42M123.25M
Retained Earnings(9.21M)(24.17M)(31.55M)(34.35M)(46.58M)
Accumulated OCI1.57M2.48M3.4M4.01M5.37M
Other Stockholders Equity(33.68K)0831.83K455.57K0
Minority Interest00000
Total Equity19.4M10.54M6.6M5.54M82.04M
Total Debt0139.91K73.55K118.96K125.78K
Net Debt(19.76M)(11.49M)(6.67M)(5.6M)(82.78M)

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.